Nuvectis Pharma, Inc.(NVCT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
Unusual Activity in NVCT
Events flagged as statistical outliers against NVCT's own multi-year baseline — not fixed dollar thresholds.
- Insider cluster2026-06-30
2 insiders bought $1,166,000 of NVCT in 30 days — 4.0σ above this company's 2-year norm
View source filing →
NVCT Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Nuvectis Pharma, Inc. (NVCT), a Healthcare sector company. NVCT is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of NVCT by reported 13-F value include TANG CAPITAL MANAGEMENT, BlackRock, Soleus Capital Management, L.P., based on the most recent SEC filings. NVCT trades on the Nasdaq exchange and files with the SEC under CIK 1875558. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nuvectis Pharma, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-7.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-39.2% YoYOperating Income
-38.9% YoYEPS (Diluted)
-18.9% YoYTotal Assets
+70.4% YoYOp. Cash Flow
-30.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-26.4M -39.2% | $-19.0M +14.6% | $-22.3M -16.6% | $-19.1M -48.1% | $-12.9M | — |
| Operating Income | $-27.6M -38.9% | $-19.8M +13.3% | $-22.9M -19.0% | $-19.2M -49.2% | $-12.9M | — |
| EPS (Diluted) | $-1.32 -18.9% | $-1.11 +22.4% | $-1.43 +5.3% | $-1.51 +50.0% | $-3.02 | — |
| Total Assets | $31.7M +70.4% | $18.6M -3.0% | $19.2M -6.0% | $20.4M +206.5% | $6.7M | — |
| Operating Cash Flow | $-16.0M -30.7% | $-12.2M +23.2% | $-16.0M -17.7% | $-13.6M -42.7% | $-9.5M | — |
Get alerted when NVCT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Nuvectis Pharma, Inc. including:
Top Institutional Holders of NVCT
TANG CAPITAL MANAGEMENT LLC
$28.5M1,550,000 shBlackRock, Inc.
$18.4M1,001,285 shSoleus Capital Management, L.P.
$18.4M1,000,000 shPERCEPTIVE ADVISORS LLC
$18.4M1,000,000 shVANGUARD CAPITAL MANAGEMENT LLC
$16.0M872,482 shIRIDIAN ASSET MANAGEMENT LLC/CT
$14.3M777,078 shGEODE CAPITAL MANAGEMENT, LLC
$8.0M432,273 shOccam Crest Management LP
$7.4M357,147 shSPHERA FUNDS MANAGEMENT LTD.
$7.0M382,945 shBALDWIN WEALTH PARTNERS LLC/MA
$7.0M382,015 sh
| Fund | Value | Shares |
|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | $28.5M | 1,550,000 |
| BlackRock, Inc. | $18.4M | 1,001,285 |
| Soleus Capital Management, L.P. | $18.4M | 1,000,000 |
| PERCEPTIVE ADVISORS LLC | $18.4M | 1,000,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $16.0M | 872,482 |
| IRIDIAN ASSET MANAGEMENT LLC/CT | $14.3M | 777,078 |
| GEODE CAPITAL MANAGEMENT, LLC | $8.0M | 432,273 |
| Occam Crest Management LP | $7.4M | 357,147 |
| SPHERA FUNDS MANAGEMENT LTD. | $7.0M | 382,945 |
| BALDWIN WEALTH PARTNERS LLC/MA | $7.0M | 382,015 |
More Healthcare Companies
View all Healthcare →Put NVCT on your watchlist
Track score changes the day Nuvectis Pharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NVCT a good stock to buy?
13F Pro's AI-powered analysis of Nuvectis Pharma, Inc. (NVCT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NVCT are available on the NVCT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NVCT is classified as a small company.
Which hedge funds own NVCT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NVCT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Nuvectis Pharma, Inc.'s investment landscape.